Showing results (141-150 of 147) with videos related to
Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 147 results.
Annals of Hematology|May 11, 2026
Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCTVíctor Torrecillas-Mayayo, Aina Oliver-Caldes, Nuria Martínez-Cibrian, et al.Clinical Lymphoma, Myeloma & Leukemia|February 15, 2025
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation TrialsDavid F Moreno, Albert Oriol, Javier de la Rubia, et al.Cancer Immunology Research|June 27, 2025
Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is LimitedLuis Gerardo Rodríguez-Lobato, Oriol Cardús, Joan Mañé-Pujol, et al.Journal for Immunotherapy of Cancer|December 8, 2021
First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myelomaAina Oliver-Caldes, Raquel Jiménez, Marta Español-Rego, et al.Frontiers in Immunology|January 23, 2026
m-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsisAna Belén Moreno-Castaño, Sara Fernández, Helena Brillembourg, et al.Blood Advances|November 27, 2024
Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myelomaInés Zugasti, Marta Tormo-Ratera, Aina Oliver-Caldés, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2024
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple MyelomaAina Oliver-Caldes, Marta Español-Rego, Aintzane Zabaleta, et al.Pageof 15